Vascular Flow Technologies Announces Spiral Flow Arteriovenous Graft Study Results

April 17, 2015

Vascular Flow Technologies has announced positive test results for its Spiral Flow arteriovenous graft, which the UK devicemaker claims demonstrated superior efficacy when paired against polytetrafluoroethylene grafts, the standard of care.

The European trial’s midterm results indicate the Spiral Flow AV graft had 18-month primary patency rates of 72 percent while PTFE graft rates were only 36.7 percent, the company says.

The graft’s technology mimics natural blood flow, providing for better patient outcomes, the devicemaker claims. The grafts were used only if patients were not acceptable candidates for autologous fistula procedures.

The company followed up with patients, carrying out duplex mapping every three months and initiated duplex scanning if there were indications shunt failure might occur. Four patients had shunt occlusions, two of which were treated with thrombectomies, the devicemaker says.

The Spiral Flow AV graft is CE Mark- and FDA-approved. — Jason Scott